Literature DB >> 1540037

A long-term immunological study of childhood onset systemic lupus erythematosus.

C K Ting1, K H Hsieh.   

Abstract

Immunological dysregulation is an important cause of the development of systemic lupus erythematosus (SLE). Serological evaluation has been useful in the clinical management of patients and as a prognostic indicator. Sixteen patients who developed SLE as children were followed up for more than three years and immunological data collected. The results showed that (a) complement C3 concentration was lower in the active stage of SLE, especially during a major clinical exacerbation, but rarely preceded a major flare up. The concentration was often normal during the mildly to moderately active stage. In contrast, a low complement C4 concentration often preceded a major clinical exacerbation and could be of longer duration, sometimes persisting regardless of disease activity. (b) A T cell subset distribution study showed persistently low CD4 positive T cells in the peripheral blood of patients with SLE during the long term follow up, strongly suggesting that the intrinsic defect is mainly localised in T helper/inducer cells. These abnormal cellular defects did not tend to return to normal even in long term remission. (c) The persistently higher serum interleukin 2 and interleukin 2 receptor concentrations in SLE strongly suggested that the T cells were preactivated in vivo and that these phenomena might persist even in remission. (d) The best single parameter for predicting active SLE was anti-dsDNA. It was highly correlated with disease activity in most patients, and the asymptomatic increase of anti-dsDNA (greater than or equal to 60 U/ml, radioimmunoassay) was often followed by a major clinical exacerbation, especially in patients with a simultaneously low complement C4 concentration, suggesting that it might be an important warning sign of a major flare up. High dose steroids are indicated in this group of patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1540037      PMCID: PMC1004617          DOI: 10.1136/ard.51.1.45

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  37 in total

1.  Human interleukin 2. Detection at the picomolar level by sandwich enzyme immunoassay.

Authors:  B Ferrua; C Aussel; M Fehlmann
Journal:  J Immunol Methods       Date:  1987-03-12       Impact factor: 2.303

2.  Impaired expression of high affinity interleukin 2 receptor on activated lymphocytes from patients with systemic lupus erythematosus.

Authors:  H Ishida; S Kumagai; H Umehara; H Sano; Y Tagaya; J Yodoi; H Imura
Journal:  J Immunol       Date:  1987-08-15       Impact factor: 5.422

3.  Prognostic significance of DNA-binding capacity patterns in patients with lupus nephritis.

Authors:  M K Adler; A Baumgarten; B Hecht; N J Siegel
Journal:  Ann Rheum Dis       Date:  1975-10       Impact factor: 19.103

4.  Useful laboratory measurements in the management of systemic lupus erythematosus.

Authors:  W J Morrow; D A Isenberg; A Todd-Pokropek; H F Parry; M L Snaith
Journal:  Q J Med       Date:  1982

5.  Correlation of T and B cell activities in vitro and serum IL-2 levels in systemic lupus erythematosus.

Authors:  Y P Huang; L H Perrin; P A Miescher; R H Zubler
Journal:  J Immunol       Date:  1988-08-01       Impact factor: 5.422

6.  Systemic lupus erythematosus. Follow-up study of 148 patients. II: Predictive factors of importance for course and outcome.

Authors:  P Halberg; B Alsbjørn; J T Balslev; I Lorenzen; J Gerstoft; S Ullman; A Wiik
Journal:  Clin Rheumatol       Date:  1987-03       Impact factor: 2.980

7.  Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE).

Authors:  M Linker-Israeli; A C Bakke; R C Kitridou; S Gendler; S Gillis; D A Horwitz
Journal:  J Immunol       Date:  1983-06       Impact factor: 5.422

8.  Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus.

Authors:  A J Swaak; J Groenwold; W Bronsveld
Journal:  Ann Rheum Dis       Date:  1986-05       Impact factor: 19.103

9.  Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro.

Authors:  L A Rubin; C C Kurman; M E Fritz; W E Biddison; B Boutin; R Yarchoan; D L Nelson
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

10.  Characterization of T lymphocyte subpopulations responsible for deficient interleukin 2 activity in patients with systemic lupus erythematosus.

Authors:  Y Murakawa; S Takada; Y Ueda; N Suzuki; T Hoshino; T Sakane
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

View more
  8 in total

1.  Systemic lupus erythematosus (SLE) in childhood: analysis of clinical and immunological findings in 34 patients and comparison with SLE characteristics in adults.

Authors:  J Font; R Cervera; G Espinosa; L Pallarés; M Ramos-Casals; S Jiménez; M García-Carrasco; L Seisdedos; M Ingelmo
Journal:  Ann Rheum Dis       Date:  1998-08       Impact factor: 19.103

2.  B cell activation in clinically quiescent systemic lupus erythematosus (SLE) is related to immunoglobulin levels, but not to levels of anti-dsDNA, nor to concurrent T cell activation.

Authors:  P E Spronk; B T vd Gun; P C Limburg; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1993-07       Impact factor: 4.330

Review 3.  New advances in measurement of complement activation: lessons of systemic lupus erythematosus.

Authors:  Chau-Ching Liu; Susan Manzi; Natalya Danchenko; Joseph M Ahearn
Journal:  Curr Rheumatol Rep       Date:  2004-10       Impact factor: 4.592

4.  Serum-soluble CXCL16 in juvenile systemic lupus erythematosus: a promising predictor of disease severity and lupus nephritis.

Authors:  Arwa Mohammad Hassan; Nessma Mohamed Ahmed Farghal; Doaa Salah Hegab; Wesam Salah Mohamed; Hend Hassan Abd-Elnabi
Journal:  Clin Rheumatol       Date:  2018-07-13       Impact factor: 2.980

5.  Systemic lupus erythematosus: clinical manifestations and immunological parameters in 194 patients. Subgroup classification of SLE.

Authors:  J Antolin; M J Amerigo; A Cantabrana; A Roces; P Jimenez
Journal:  Clin Rheumatol       Date:  1995-11       Impact factor: 2.980

Review 6.  The epidemiology of systemic lupus erythematosus.

Authors:  Sònia Jiménez; Ricard Cervera; Josep Font; Miguel Ingelmo
Journal:  Clin Rev Allergy Immunol       Date:  2003-08       Impact factor: 8.667

7.  Differential manifestations of prepubescent, pubescent and postpubescent pediatric patients with systemic lupus erythematosus: A retrospective study of 96 Chinese children and adolescents.

Authors:  Li-Lan Chiang; Yu-Tsan Lin; Hung-Yi Chan; Bor-Luen Chiang
Journal:  Pediatr Rheumatol Online J       Date:  2012-05-02       Impact factor: 3.054

8.  Associations of lymphocyte subpopulations with clinical phenotypes and long-term outcomes in juvenile-onset systemic lupus erythematosus.

Authors:  Butsabong Lerkvaleekul; Nopporn Apiwattanakul; Kanchana Tangnararatchakit; Nisa Jirapattananon; Supanart Srisala; Soamarat Vilaiyuk
Journal:  PLoS One       Date:  2022-02-07       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.